News & Analysis on Clinical Trial Services & Contract Research And Development
Three chemicals companies - Akzo Nobel, the Hoechst unit of Sanofi-Aventis and Total subsidiary Arkema - have been fined €217 million by the European Commission for operating a cartel in the market for monochloroacetic acid (MCAA).
Growth in Asian and South American markets boost sales for Danish firm Chr Hansen, counterbalancing a fall in revenue in North America for the first quarter of the year.
US peptide developers Helix BioMedix has entered into collaboration with Smith & Nephew, which aims to focus on the development of HB50, the company's lead topical anti-infective peptide.
The European Parliament embarked on a new round of deliberations over the controversial REACH legislation last week, amid intense lobbying by groups representing the chemicals industry, animal rights activists and environmentalists.
US researchers have developed a faster, more efficient way to produce a wide variety of nanoparticle-based drug delivery systems, using DNA molecules to bind the particles together.
Regulatory action on the COX-2 inhibitors was still a possibility as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) held hearings with Pfizer, Merck Sharp & Dohme and Novartis regarding the safety over the drug...
Increasing numbers of suppliers are being forced to stop providing their services to companies and organisations engaged in animal research, according to the Association of the British Pharmaceutical Industry.
Figures released by the Association of the British Pharmaceutical Industry (ABPI) has revealed that the level of intimidation posed by animal extremists reaches as far as the suppliers who do business with companies involved with animal research.
Vitra Bioscience has introduced a new nuclear translocation application, a new method enabling the measurement of cytoplasm-to-nucleus translocation, a critical indicator of cellular response to various drug treatments.
Allos Theraputics have initiated a phase 1 study of its investigational drug PDX (pralatrexate) that has so far proved effective against non-small cell lung cancer (NSCLC). This treatment has the potential to surpass Methotrexate as the preferred...